Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $571 Mil. Illumina's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $2,044 Mil. Illumina's annualized EBITDA for the quarter that ended in Mar. 2022 was $948 Mil.
Illumina's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 was 2.76.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Illumina's Debt-to-EBITDA or its related term are showing as below:
ILMN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08 Med: 1.76 Max: 2.93
Current: 2.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Illumina was 2.93. The lowest was 1.08. And the median was 1.76.
ILMN's Debt-to-EBITDA is ranked worse than 69.84% of 126
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.25
vs ILMN: 2.19
Illumina Debt-to-EBITDA Historical Data
The historical data trend for Illumina's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Debt-to-EBITDA
1.08
1.77
1.39
1.75
2.12
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Debt-to-EBITDA
3.05
2.24
1.27
3.38
2.76
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Debt-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Illumina's Debt-to-EBITDA falls into.
Illumina Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2022) EBITDA data.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Illumina Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Illumina's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
4.23(1.9%) Volume: 101,554 10:05AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
